Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Posts 10-Percent Rise in Q1 Revenues as Bio-Analytical Segment Grows 6 Percent

NEW YORK, Feb. 13 (GenomeWeb News) - Agilent Technologies today reported a 10-percent rise in first-quarter revenues as orders in its Bio-Analytical Measurement segment rose 6 percent.


The company's total revenues in the quarter ended Dec. 31, 2005, increased to $1.34 billion from $1.21 billion in the year-ago period. Revenues from the Bio-Analytical Measurement segment climbed 5 percent to $373 million from $354 million, while orders rose to $378 million in the quarter from $356 million a year earlier.


Agilent's research and development spending in the first quarter rose to $189 million from $175 million in the year-ago quarter.


The company's first-quarter adjusted net income jumped to $154 million, or $.32 per share, from $71 million, or $.15 per share, the year before. These numbrs excluded charges related to the planned spin off of Agilent's Semiconductor Test Solutions unit and the reduction in infrastructure costs, as well as related non-cash stock compensation expenses.


As of Jan. 31, Agilent had cash and cash equivalents totaling $2.7 billion.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.